Platelet activation and inhibition in unstable coronary syndromes

American Journal of Cardiology

Volumn 80, Issue 5 A, 1997, Pages

  Patrono, Carlo ^a   Renda, Guilia ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFINPYRAZONE; THROMBOXANE A2; TICLOPIDINE;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS;

EID: 0030879804     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00484-0     Document Type: Conference Paper

References (36)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
2. Davies MJ, Thomas AC. Plaque fissuring - The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 53:1985;363-373.
3. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 304:1981;685-691.
4. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, Willerson JT. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 73:1986;572-578.
5. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 54:1976;365-370.
6. Eichhorn EJ, Grayburn PA, Willard JE. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol. 17:1991;43-52.
7. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 71:1985;699-708.
8. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 63:((Suppl)):1989;114E-120E.
9. Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesion. Experimental evidence and potential clinical implications. Circulation. 80:1989;198-205.
10. Woolf N, Davies MJ. Interrelationship between atherosclerosis and thrombosis. Fuster V, Verstraete M. Thrombosis in Cardiovascular Disorders. 1992;41-77 WB Saunders, Philadelphia.
11. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 72:1975;2294-2298.
12. 2 as an amplifying signal for other agonists. Am J Cardiol. 68:((Suppl)):1991;11B-15B.
13. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 10:1989;453-458.
14. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 315:1986;983-989.
15. Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol. 10:1987;988-1006.
16. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GV, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 63:1990;163-168.
17. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 72:1975;3073-3076.
18. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA. 85:1988;1412-1416.
19. Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 5:1991;2304-2312.
20. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 311:1984;1206-1211.
21. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
22. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, Le Winter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, De Mots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 309:1983;396-403.
23. Cairns JA, Gent M, Singer J. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 313:1985;1369-1375.
24. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell' Angina Instabile Group. Circulation. 82:1990;17-26.
25. Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs. 34:1987;222-262.
26. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet. 26:1994;347-355.
27. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 69:1987;180-186.
28. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
29. Patrono C. Unstable coronary artery disease: need for long term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for. Cardiovasc Res. 33:1997;295-296.
30. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303:1980;897-902.
31. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. ii:1988;349-360.
32. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 332:1995;80-85.
33. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficaries - patterns of use and outcomes. Circulation. 92:1995;2841-2847.
34. Cairns JA, Lewis HD Jr, Meade TW, Sutton GC, Théroux P. Antithrombotic agents in coronary artery disease. Chest. 108:1995;380S-400S.
35. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 330:1994;1287-1294.
36. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J. 17:1996;9-18.